We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

70 hedge funds and large institutions have $28.2M invested in Galectin Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $2.84M | Put options by funds: $1.23M

11% more capital invested

Capital invested by funds: $25.3M → $28.2M (+$2.9M)

1.33% less ownership

Funds ownership: 13.62% → 12.29% (-1.3%)

7% less funds holding

Funds holding: 75 → 70 (-5)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

48% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 23

Holders
70
Holders Change
-5
Holders Change %
-6.67%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
12
Reduced
23
Closed
14
Calls
$2.84M
Puts
$1.23M
Net Calls
+$1.61M
Net Calls Change
+$551K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$447K
2
KeyBank National Association
KeyBank National Association
Ohio
+$339K
3
Capstone Investment Advisors
Capstone Investment Advisors
New York
+$143K
4
QAM
QCI Asset Management
New York
+$102K
5
Citadel Advisors
Citadel Advisors
Florida
+$82.8K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.22M
2
Millennium Management
Millennium Management
New York
-$740K
3
TEE
Tibra Equities Europe
United Kingdom
-$316K
4
Marshall Wace
Marshall Wace
United Kingdom
-$152K
5
ECM
ExodusPoint Capital Management
New York
-$135K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
51
Cutler Group
California
$13K +$11.9K +3,500 New
TRCT
52
Tower Research Capital (TRC)
New York
$12K -$24.2K -7,129 -70%
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
$10K -$9.82K -2,897 -54%
IA
54
IFP Advisors
Florida
$10K +$6.78K +2,000 +400%
Barclays
55
Barclays
United Kingdom
$9K -$14.2K -4,200 -64%
UBS Group
56
UBS Group
Switzerland
$8K +$3.35K +988 +99%
PMFA
57
Plante Moran Financial Advisors
Michigan
$7K – – –
APA
58
American Portfolios Advisors
New York
$4K – – –
BCPWM
59
Bradley & Co Private Wealth Management
Florida
$4K – – –
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$2.49K – – –
RFA
61
Reilly Financial Advisors
California
$2K +$508 +150 New
AWM
62
Accel Wealth Management
Iowa
$1K – – –
GRP
63
Global Retirement Partners
California
$1K – – –
HI
64
Harbour Investments
Wisconsin
$1K – – –
SIC
65
Salem Investment Counselors
North Carolina
$1K – – –
TWA
66
TCI Wealth Advisors
Arizona
$1K – – –
JCM
67
Jacobi Capital Management
Pennsylvania
$1K +$763 +225 New
RE
68
RBC Europe
United Kingdom
$155 – – –
TEE
69
Tibra Equities Europe
United Kingdom
– -$316K -98,700 Closed
Marshall Wace
70
Marshall Wace
United Kingdom
– -$152K -47,509 Closed
ECM
71
ExodusPoint Capital Management
New York
– -$135K -42,042 Closed
D.E. Shaw & Co
72
D.E. Shaw & Co
New York
– -$66K -20,607 Closed
LP
73
LMR Partners
United Kingdom
– -$62K -19,285 Closed
SFI
74
Susquehanna Fundamental Investments
Pennsylvania
– -$50K -15,600 Closed
XT
75
XTX Topco
Cayman Islands
– -$40K -12,419 Closed
1 2
3
4

GALT Hedge Fund Activity: Q3 2021 in Review

70 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2021, worth a combined $28.2M — up 11% from $25.3M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of GALT and 9 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 12 added.

The largest buyer was Geode Capital Management, adding an estimated $447K. The largest seller was Renaissance Technologies, cutting an estimated $1.22M.

  • 70 institutional investors held Galectin Therapeutics (GALT) as of Q3 2021, down from 75 in Q2 2021.
  • Funds reported $28.2M of Galectin Therapeutics stock for Q3 2021, up 11% quarter-over-quarter.
  • 9 funds opened new Galectin Therapeutics positions in Q3 2021 and 14 closed out, a net change of -5 holders.
  • The largest Galectin Therapeutics buyer in Q3 2021 was Geode Capital Management, an estimated $447K added.
  • The largest Galectin Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $1.22M sold.

Based on aggregated 13F filings for Q3 2021.